Omniose
St. Louis, US · 1 known investors
Omniose develops a platform for bioconjugate vaccine development using glycoconjugation technology to create vaccines against bacterial pathogens like Group B Streptococcus and Klebsiella pneumoniae. The company works with pharmaceutical and research partners to advance vaccine candidates through preclinical and clinical development.
BiotechDeep TechHealthtechMedical Devices
Founders & leadership
DH
Dr. HardingPrimary Founder
DS
Dr. Szymanski
MF
Mario F. Feldman
DP
Dr. Projan
VP
Viliam Pavliak
DC
Dr. Cooke
BM
Benjamin Moutier
MF
Mario FeldmanFounder, Scientific Founder
CH
Christian HardingFounder
Investors · 1
In the news
- Omniose - 2025 Company Profile, Funding & Competitors - Tracxntracxn.com · 2022
- Omniose Receives $3.6M Grant from NIHfinsmes.com · 2022
- Publications | Omnioseomniose.com · 2022
- Blog | Omnioseomniose.com · 2018